Jacob Young, MD
Role: Presenting Author
Disclosure Status: Complete
Disclosure: Nothing to Disclose
Signed: Jacob S Young (10/18/2025, 4:37 PM)
No financial relationships or conflicts of interest.
Abstract
Topic
Tumor
Introduction
Data on incidental brain findings remain limited despite the increase in MRI frequency. We analyzed brain findings in 78,000 individuals undergoing preventive screening whole-body MRI to determine the incidence, types, and demographic distribution of intracranial abnormalities.
Methods
We reviewed screening whole-body MRIs performed between January 2024 and June 2025 across 21 Prenuvo clinics. All scans were non-contrast, multiparametric studies on 1.5T MRI systems. The brain protocol included T1 MPRAGE, FLAIR, TOF MRA, and whole-body sequences (STIR, DWI). Radiologists used a standardized synoptic template and a 5-point Clinically Significant Diagnosis (CSD) scale. Brain findings with CSD 3 (low concern), 4 (moderate, timely follow-up), and 5 (major, expedited follow-up) were included.
https://www.abstractscorecard.com/cfp/submit/submissions/summary/view.asp?EventKey=RFPFZXXJ&SubmissionID=2264299 1/3
10/18/25, 10:43 PM Preview - 2026 AANS Call for Abstracts - 2026 AANS Annual Scientific Meeting Results
Abstract Title: Incidental Brain Findings in over 78,000 Individuals from the General Population Undergoing Preventive Whole Body MRI
Of 78,800 individuals, 5,637 (7.1%) had at least one brain finding with CSD ≥3 (mean age 50.6 ± 12.7 years; 44% male). The most common were intracranial aneurysm (IA, 2.2%, n=1,759), small vessel ischemia (0.95%, n=753), brain infarct (0.65%, n=529), indeterminate brain lesion (IBL, 0.7%, n=555), narrowed intracranial arteries (0.38%, n=310), meningioma (0.22%, n=181), and pituitary mass (0.19%, n=152). Rare findings included AVM (0.04%), glioma (0.02%), and metastases (0.01%).
Among IAs, 67% were female, 87% in anterior circulation, and 2.6% >7 mm in size; 17.3% CSD 4, 0.3% CSD 5. IBLs (55.6% female; 51.6% aged 35–54) measured 0.3–5.8 cm, with 34.5% intra-axial, 21.2% extra-axial, 7.2% CSD 4, and 0.7% CSD 5. Meningiomas (0.3-5.0 cm; 76% female; 55% aged 45–64) were CSD 4 in 5.5% and CSD 5 in 1.1%.
Among individuals with indeterminate brain lesions (IBL), 55.6% were female, and 51.6% were aged 35–54 years. IBL ranged from 0.3-5.8 cm in size, with 34.5% intra-axial, 21.2% extra-axial, and the remainder unspecified. Among IBL, 40 (7.2%) were CSD 4 and 4 (0.7%) were CSD 5.
Conclusion
In a large general population, CSD ≥3 brain findings occurred in 7% of individuals. These findings align with population MRI studies (e.g., Rotterdam) and highlight the importance of silent but actionable brain pathology detected on screening MRI.
Additional Information
Has the work presented in this abstract or substantially similar work been presented or published previously?
No
If yes, please explain.
Is your work pending FDA approval?
No
Are you an employee of industry? (i.e: Eli Lilly, Pfizer, etc.)
No
Is this abstract submission the result of research funding from the AANS, the Neurosurgery Research and Education Foundation (NREF) or one of the AANS/CNS Sections?
No
Does your abstract utilize data from NeuroPoint Alliance's Quality Outcomes Database (QOD) formerly known as N2QOD?
No
Please indicate if presenting author is a medical student, resident or fellow.
N/A
Medical Students, Residents and Fellows please provide Senior Author’s name and e-mail in box below
If N/A, please type N/A in box below
https://www.abstractscorecard.com/cfp/submit/submissions/summary/view.asp?EventKey=RFPFZXXJ&SubmissionID=2264299 2/3
10/18/25, 10:43 PM Preview - 2026 AANS Call for Abstracts - 2026 AANS Annual Scientific Meeting N/A
Abstract Title: Incidental Brain Findings in over 78,000 Individuals from the General Population Undergoing Preventive Whole Body MRI
All submitted abstracts will automatically be considered for applicable awards. Visit the 2026 AANS Annual Meeting Abstract Center for a list of some of the awards under consideration. Please review the award descriptions and eligibility criteria to understand which awards your abstract may be eligible for. Please note: Only the Presenting Author is eligible to receive an award. Other individuals listed in the author block will not be considered for award recognition.
I acknowledge that all submitted abstracts will automatically be considered for applicable awards.
Personal Information Consent
Personal Information Consent
I have read and understand the information above. I consent to the AANS retaining personal information about me and using such information to send emails and other communications to me. I further consent to the AANS sharing my personal information with its third-party vendors, when necessary. I have read and understand the information above. I consent to allow the AANS to share my name and mailing address with ineligible companies or their agents.
Policy Regarding Harassment and Disruptive Behavior at Meetings and Courses*
I have read the AANS Policy Regarding Harassment and Disruptive Behavior at Meetings and Courses and agree to comply in all respects with the policy.
